Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis Bullosa
Sponsor: Krystal Biotech, Inc.
Summary
KB803-EYE-01 is a Phase 3 double-blind, randomized, placebo-controlled, crossover study to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
Official title: A Double-Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa
Key Details
Gender
All
Age Range
6 Months - Any
Study Type
INTERVENTIONAL
Enrollment
16
Start Date
2025-06-20
Completion Date
2026-12
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
KB803
Ophthalmic suspension of replication-defective, non-integrating herpes simplex virus (HSV-1) expressing the human collagen VII protein
Placebo
Vehicle
Locations (5)
Mission Dermatology Center
Rancho Santa Margarita, California, United States
Skin Research Institute
Coral Gables, Florida, United States
UMass Memorial Medical Center
Worcester, Massachusetts, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Texas Dermatology and Laser Specialists
San Antonio, Texas, United States